Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Madrigal (NASDAQ:MDGL) announced an exclusive global license from Pfizer for ervogastat, a Phase 2 oral DGAT-2 inhibitor, plus rights to two additional early-stage MASH assets. Madrigal paid an upfront $50 million (recorded in Q4 2025) and is eligible for milestone payments and royalties. Ervogastat showed Phase 2 MRI-PDFF results (72% ≥30% liver fat reduction; 61% ≥50%), and Madrigal plans a 2026 drug‑interaction study with Rezdiffra and FDA consultation on a Phase 2 combination trial.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced on December 18, 2025 that it granted inducement equity awards on December 15, 2025 to four new non-executive employees under its 2025 Inducement Plan.
The awards totalled 1,394 time-based restricted stock units, approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). All RSUs vest in four equal annual installments on each of the first through fourth anniversaries of the grant date, and vesting is subject to each employee’s continued employment on the applicable vesting date.
Madrigal Pharmaceuticals (NASDAQ: MDGL) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 PM PST. The presentation will be broadcast live and accessible via the company's Investor Relations Events and Presentations page, with a replay available after the event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced equity inducement awards granted on December 1, 2025 to 24 new non-executive employees under its 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The grants comprise options to purchase 4,099 shares and 14,630 time-based restricted stock units. Options carry an exercise price of $579.45 per share, equal to the closing price on the grant date.
Options vest 25% after one year, then 6.25% each quarterly anniversary thereafter; RSUs vest in four equal annual installments. All vesting is conditional on continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on November 15, 2025 to three new non-executive employees under its 2025 Inducement Plan. The independent Compensation Committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4).
The grants total 2,125 time-based restricted stock units (RSUs), vesting in four equal annual installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ: MDGL) will participate in three investor conference fireside chats in late November and early December 2025. Presentations and live webcasts are scheduled as follows: Jefferies Global Healthcare Conference in London on Nov 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET); Evercore Healthcare Conference on Dec 2, 2025 at 4:15 P.M. ET; and Piper Sandler Healthcare Conference on Dec 3, 2025 at 1:30 P.M. ET. All fireside chats will be webcast live and can be accessed via Madrigal’s Investor Relations Events page.
Madrigal (NASDAQ: MDGL) reported two-year Phase 3 MAESTRO-NAFLD-1 data showing that Rezdiffra (resmetirom) produced statistically significant improvements in multiple noninvasive imaging tests and biomarkers in patients with compensated MASH cirrhosis (F4c).
Key findings: n=122 (113 completed two years), subgroup with platelets <100,000/µL (n=30) showed VCTE reductions of -7.9 kPa (platelets <100k) and -6.4 kPa (platelets >100k), two-thirds of patients shifted to lower Baveno CSPH risk by Year 2, and pooled QoL improvements were seen across MAESTRO (n=1,323). Treatment interruptions (mean 77–111 days) led to reversible loss of benefit. Rezdiffra is approved for noncirrhotic MASH (F2–F3); safety in cirrhosis is not established.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on November 1, 2025 to 18 new non-executive employees under its 2025 Inducement Plan.
The board’s independent Compensation Committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4). In aggregate the new hires received 7,301 time-based restricted stock units (RSUs), which vest in four equal annual installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ: MDGL) reported Q3 2025 results and corporate updates on Nov. 4, 2025. Q3 net sales of Rezdiffra were $287.3 million and the company reports >29,500 patients on therapy and >10,000 prescribers. Madrigal lists a new Orange Book patent for Rezdiffra providing U.S. protection into 2045 and launched Rezdiffra in Germany after European Commission conditional approval. Madrigal closed a global license with CSPC for an oral GLP-1 (MGL-2086) expected to enter the clinic in 1H 2026. Cash and marketable securities totaled $1.1 billion as of Sept. 30, 2025.
Madrigal (NASDAQ: MDGL) will present new clinical and real-world data for Rezdiffra (resmetirom) at AASLD The Liver Meeting, Nov 7-11, 2025 in Washington, D.C.
Key items include two oral presentations (Nov 9 and Nov 10) reporting two-year biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial, posters on response durability and effects after treatment interruption, and multiple real-world analyses of Rezdiffra use.
Notable data cited: Rezdiffra achieved primary endpoints in the MAESTRO-NASH biopsy trial and 91% of patients on 100 mg showed VCTE improvement or stabilization at one year.